Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,808,855
  • Shares Outstanding, K 126,525
  • Annual Sales, $ 781,370 K
  • Annual Income, $ -197,880 K
  • EBIT $ 80 M
  • EBITDA $ 93 M
  • 60-Month Beta 0.26
  • Price/Sales 2.88
  • Price/Cash Flow N/A
  • Price/Book 6.80

Options Overview Details

View History
  • Implied Volatility 62.96% (-2.70%)
  • Historical Volatility 72.18%
  • IV Percentile 45%
  • IV Rank 36.50%
  • IV High 97.27% on 07/28/25
  • IV Low 43.24% on 01/22/26
  • Expected Move (DTE 29) 2.82 (12.38%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 119
  • Volume Avg (30-Day) 243
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 22,042
  • Open Int (30-Day) 21,702
  • Expected Range 19.98 to 25.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.39
  • Number of Estimates 11
  • High Estimate -0.27
  • Low Estimate -0.55
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -34.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.26 +18.38%
on 01/20/26
24.10 -5.39%
on 02/05/26
+2.86 (+14.34%)
since 01/16/26
3-Month
19.26 +18.38%
on 01/20/26
27.46 -16.97%
on 01/09/26
+3.35 (+17.22%)
since 11/19/25
52-Week
16.10 +41.61%
on 05/15/25
30.48 -25.20%
on 10/28/25
-5.59 (-19.69%)
since 02/19/25

Most Recent Stories

More News
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting

Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ®   (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE...

APLS : 22.80 (+2.70%)
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results

WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter...

APLS : 22.80 (+2.70%)
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

NEW YORK , Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600:

CADE : 42.11 (-1.66%)
HBAN : 17.85 (-0.22%)
CIVI : 27.38 (-1.37%)
RYN : 22.55 (-4.04%)
APLS : 22.80 (+2.70%)
AHR : 52.17 (-0.19%)
BROS : 49.73 (-6.91%)
AMRX : 14.60 (-1.68%)
LZ : 7.05 (+1.15%)
AEIS : 320.64 (-0.22%)
FITB : 52.90 (-1.43%)
PCH : 41.73 (+0.05%)
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Full-year 2025 preliminary 1 U.S. net product revenues of $689 million SYFOVRE ® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled...

APLS : 22.80 (+2.70%)
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 44 th Annual J.P. Morgan Healthcare Conference on...

APLS : 22.80 (+2.70%)
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Consistent...

APLS : 22.80 (+2.70%)
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:...

APLS : 22.80 (+2.70%)
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous...

APLS : 22.80 (+2.70%)
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November...

APLS : 22.80 (+2.70%)
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI ® (pegcetacoplan) in the first two months since...

APLS : 22.80 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 24.36
2nd Resistance Point 23.59
1st Resistance Point 23.19
Last Price 22.80
1st Support Level 22.02
2nd Support Level 21.25
3rd Support Level 20.85

See More

52-Week High 30.48
Fibonacci 61.8% 24.99
Fibonacci 50% 23.29
Last Price 22.80
Fibonacci 38.2% 21.59
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar